|
|
Article: FDA Panel Unanimously Recommends Approval of Gilead Sciences' VISTIDE for CMV Retinitis; VISTIDE is first in a new class of potent, long-acting antivirals.
- Article from:
- Business Wire
- Article date:
- March 18, 1996
CopyrightCOPYRIGHT 1996 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
FOSTER CITY, Calif.--(HealthWire)--March 18, 1996--Gilead Sciences, Inc. (NASDAQ: GILD) announced that on Friday, March 15, a U.S. Food and Drug Administration (FDA) advisory committee unanimously recommended approval of VISTIDE(R) (cidofovir injection) as a treatment for cytomegalovirus (CMV) retinitis in patients with AIDS.
VISTIDE is the first nucleotide analogue to be recommended for FDA approval and represents a new class of antiviral therapeutics.
The unanimous recommendation came following a review of data from three clinical studies demonstrating that treatment with VISTIDE results in a statistically significant delay in the progression of CMV ...